XML 76 R57.htm IDEA: XBRL DOCUMENT v3.25.4
Segment information - Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Indirect research and development expenses:    
Total research and development expenses $ 25,564 $ 42,236
Research and Development of Immunotherapies and Vaccines    
Direct research and development expenses:    
Total direct research and development expenses 14,594 23,709
Indirect research and development expenses:    
Total indirect research and development expenses 10,970 18,527
Total research and development expenses 25,564 42,236
Research and Development of Immunotherapies and Vaccines | Personnel-related (including share-based compensation)    
Indirect research and development expenses:    
Total indirect research and development expenses 8,413 15,867
Research and Development of Immunotherapies and Vaccines | Facility related    
Indirect research and development expenses:    
Total indirect research and development expenses 1,370 1,249
Research and Development of Immunotherapies and Vaccines | Other indirect costs    
Indirect research and development expenses:    
Total indirect research and development expenses 1,187 1,411
Research and Development of Immunotherapies and Vaccines | VTP-1000 Celiac    
Direct research and development expenses:    
Total direct research and development expenses 6,063 5,486
Research and Development of Immunotherapies and Vaccines | Barinthus legacy assets    
Direct research and development expenses:    
Total direct research and development expenses $ 8,531 $ 18,223